U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07401472) titled 'Phase 1, Single Ascending Dose Study of BW-50218 in Healthy Participants' on Jan. 26.
Brief Summary: Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants
Study Start Date: Feb. 25
Study Type: INTERVENTIONAL
Condition:
Healthy Participants Study
Intervention:
DRUG: BW-50218 Injection
Solution for injection
DRUG: Saline (0.9% NaCl)
Solution for injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd.
Disclaimer: Curated by HT Syndication....